Oral cancer prevention and the evolution of molecular-targeted drug development

Journal of Clinical Oncology

Volumn 23, Issue 2, 2005, Pages 346-356

  Lippman, Scott M ^a   Sudbø, Jon ^a   Hong, Waun Ki ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; BETA CAROTENE; BLEOMYCIN; CELECOXIB; CYCLIN D1; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ISOTRETINOIN; NONSTEROID ANTIINFLAMMATORY AGENT; ONYX 015; PELITINIB; PROTEIN P53; RETINOIC ACID RECEPTOR BETA; RETINOID; ROFECOXIB; SULINDAC; CYCLOOXYGENASE 2; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PTGS2 PROTEIN, HUMAN; TUMOR MARKER;

ANEUPLOIDY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CHROMOSOME ABERRATION; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG POTENTIATION; DRUG SYNTHESIS; DYSPLASIA; GENE MUTATION; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HEAD AND NECK CANCER; HUMAN; LARYNX CANCER; LEUKOPLAKIA; MOUTH CANCER; MOUTH LESION; MUCOSA INFLAMMATION; NASOPHARYNX CANCER; NONHUMAN; ORAL INTRAEPITHELIAL NEOPLASIA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; CARCINOMA IN SITU; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; GENETICS; METABOLISM; MOUTH TUMOR; PHARMACEUTICS; PRECANCER; RISK ASSESSMENT; RISK FACTOR;

ANEUPLOIDY; CARCINOMA IN SITU; CYCLOOXYGENASE 2; DRUG DELIVERY SYSTEMS; GREEN FLUORESCENT PROTEINS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK ASSESSMENT; RISK FACTORS; TECHNOLOGY, PHARMACEUTICAL; TUMOR MARKERS, BIOLOGICAL;

EID: 13744259558     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.09.128     Document Type: Review

References (92)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004, CA Cancer J Clin 54:8-29, 2004
2. Silverman SJ, Gorsky M: Epidemiologic and demographic update in oral cancer: California and national data-1973 to 1985. J Am Dent Assoc 120:495-499, 1990
3. Brunin F, Mosseri V, Jaulerry C, et al: Cancer of the base of the tongue: Past and future. Head Neck 21:751-759, 1999
4. Mork J: Forty years of monitoring head and neck cancer in Norway-no good news. Anticancer Res 18:3705-3708, 1998
5. Vokes EE, Weichselbaum RR, Lippman SM, et al: Head and neck cancer. N Engl J Med 328:184-194, 1993
6. Forastiere A, Koch W, Trotti A, et al: Head and neck cancer. N Engl J Med 345:1890-1900, 2001
7. Boyle P, Macfarlane GJ, Scully C: Oral cancer: Necessity for prevention strategies. Lancet 342:1129, 1993
8. Lippman SM, Hong WK: Molecular markers of the risk of oral cancer. N Engl J Med 344:1323-1326, 2001
9. Mao L, Hong WK, Papadimitrakopoulou VA: Focus on head and neck cancer. Cancer Cell 5:311-316, 2004
10. Decker J, Goldstein JC: Risk factors in head and neck cancer. N Engl J Med 306:1151-1155, 1982
11. Reibel J: Tobacco and oral diseases. Update on the evidence, with recommendations. Med Princ Pract 1:22-32, 2003 (suppl 12)
12. Mao L, Oh Y: Does marijuana or crack cocaine cause cancer? J Natl Cancer Inst 90:1182-1185, 1998
13. Casiglia J, Woo SB: A comprehensive review of oral cancer. Gen Dent 49:72-82, 2001
14. Scully C: Oral squamous cell carcinoma; from an hypothesis about a virus, to concern about possible sexual transmission. Oral Oncol 38:227-234, 2002
15. Mao L, Hong WK: How does human papillomavirus contribute to head and neck cancer development? J Natl Cancer Inst 96:978-980, 2004
16. Mork J, Lie AK, Glattre E, et al: Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 344:1125-1131, 2001
17. Campisi G, Giovannelli L, Ammatuna P, et al: Proliferative verrucous vs conventional leukoplakia: No significantly increased risk of HPV infection. Oral Oncol 40:835-840, 2004
18. Abbruzzese JL, Lippman SM: The convergence of cancer prevention and therapy in early-phase clinical drug development. Cancer Cell 6:321-326, 2004
19. Brennan JA, Boylo JO, Koch WM, et al: Association between cigarette smoking and mutation of the p53 gene in squamous cell carcinoma of the head and neck. N Engl J Med 332:712-717, 1995
20. Wu X, Lippman SM, Lee JJ, et al: Chromosome instability in lymphocytes: A potential indicator of predisposition to oral premalignant lesions. Cancer Res 62:2813-2818, 2002
21. Shin DM, Charuruks N, Lippman SM, et al: p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Prev 10:603-609, 2001
22. Slaughter DP, Southwick HW, Smejkal W: Field cancerization in oral stratified squamous epithelium: Clinical implications of multicentric origin. Cancer 6:963-968, 1953
23. Braakhuis BJ, Tabor MP, Kummer JA, et al: A genetic explanation of Slaughter's concept of field cancerization: Evidence and clinical implications. Cancer Res 63:1727-1730, 2003
24. Jang SJ, Chiba I, Hirai A, et al: Multiple oral squamous epithelial lesions: Are they genetically related? Oncogene 20:2235-2242, 2001
25. Sudbø J, Lippman SM, Lee JJ, et al: The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med 350:1405-1413, 2004
26. Maciorowski Z, Ensley JF: Clinical correlations of DNA content parameters, DNA ploidy, and s-phase fraction in head and neck cancer. In Ensley JF, Gutkind JS, Jacobs JR, et al (eds): Head and Neck Cancer Emerging Perspectives. Academic Press, San Diego, CA, 2003, pp 167-182
27. Pindborg JJ, Reichart PA, Smith CJ, et al: Histological typing of cancer and precancer of the oral mucosa. 2nd ed. London, Springer. 1997
28. Lumerman H, Freedman P, Kerpel S: Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 79:321-329, 1995
29. Karabulut A, Reibel J, Therkildsen MH, et al: Observer variability in the histologic assessment of oral premalignant lesions. J Oral Pathol Med 24:198-200, 1995
30. Sudbø J, Bryne M, Johannessen AC, et al: Comparison of histological grading and large scale genomic status (DNA ploidy) as prognostic tools in oral dysplasia. J Pathol 194:303-310, 2001
31. Anneroth G, Hansen LS: A methodologic study of histologic classification and grading of malignancy in oral squamous cell carcinoma. Scand J Dent Res 92:448-468, 1984
32. Mao L, Lee JS, Fan YH, et al: Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 2:682-685, 1996
33. Rosin MP, Cheng X, Poh C, et al: Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 6:357-362, 2000
34. Mao L: Can molecular assessment improve classification of head and neck premalignancy? Clin Cancer Res 6:321-322, 2000
35. Partridge M, Pateromichelakis S, Phillips E, et al: A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res 60:3893-3898, 2000
36. Guo Z, Yamaguchi K, Sanchez-Cespedes M, et al: Allelic losses in OraTest-directed biopsies of patients with prior upper aerodigestive tract malignancy. Clin Cancer Res 7:1963-1968, 2001
37. Epstein JB, Zhang L, Poh C, et al: Increased allelic loss in toluidine blue-positive oral premalignant lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95:45-50, 2003
38. Sen S: Aneuploidy and cancer. Curr Opin Oncol 12:82-88, 2000
39. Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature 396:643-649, 1998
40. Gardner RD, Burke DJ: The spindle checkpoint: two transitions, two pathways. Trends Cell Biol 10:154-158, 2000
41. Ghadimi BM, Sackett DL, Difilippantonio MJ, et al: Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. Genes Chromosomes Cancer 27:183-190, 2000
42. Högmo A, Munck-Wikland E, Kuylenstierna R, et al: Nuclear DNA content and p53 immunostaining in metachronous preneoplastic lesions and subsequent carcinomas of the oral cavity. Head Neck 18:433-440, 1996
43. Abdel-Salam M, Mayall BH, Chew K, et al: Which oral white lesions will become malignant? An image cytometric study. Oral Surg Oral Med Oral Pathol 69:345-350, 1990
44. Seoane J, Bascones A, Asenjo JA, et al: Flow cytometric analysis of nuclear DNA content in oral leukoplakia. Clin Otolaryngol 23:136-140, 1998
45. Sudbø J, Kildal W, Risberg B, et al: DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med 344:1270-1278, 2001
46. Sudbø J, Ried T, Bryne M, et al: Abnormal DNA content predicts the occurrence of carcinomas in non-dysplastic oral white patches. Oral Oncol 37:558-565, 2001
47. Sudbø J, Kildal W, Johannessen AC, et al: Gross genomic aberrations in precancers: Clinical implications of a long-follow-up study in oral erythroplakias. J Clin Oncol 20:456-462, 2002
48. Sudbø J, Samuelsson R, Risberg B, et al: Risk markers of oral cancer in clinically normal rnucosa as an aid in smoking cessation counselling. J Clin Oncol: in press
49. Lee JJ, Hong WK, Hittelman WN, et al: Predicting cancer development in oral leukoplakia: Ten years of translational research. Clin Cancer Res 6:1702-1710, 2000
50. Loeb LA: A mutator phenotype in cancer. Cancer Res 61:3230-3239, 2001
51. Zhang L, Poh CF, Lam WL, et al: Impact of localized treatment in reducing risk of progression of low-grade oral dysplasia: Molecular evidence of incomplete resection. Oral Oncol 37:505-512, 2001
52. Sudbø J, Reith A, Lippman SM: Dysplastic leukoplakia. N Engl J Med 350:2718-2719, 2004
53. Brennan JA, Mao L, Hruban RH, et al: Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 332:429-435, 1995
54. Talamoni M, Veraldi S, Marini D: Leukoplakia of the mouth: Comparison of therapies. Dent Cadmos 53:43-46, 1985
55. Pene F, Fletcher GH: Results in irradiation of the in situ carcinomas of the vocal cords. Cancer 37:2586-2590, 1976
56. Betz CS, Leuning A: Possibilities and limits of fluorescence diagnosis and photodynamic therapy. 2: Photodynamic therapy. HNO 52:175-192, 2004
57. Epstein JB, Wong FLW, Millner A, et al: Topical bleomycin treatment of oral leukoplakia: A randomized double-blind clinical trial. Head Neck 16:539-544, 1994
58. Sporn MB, Lippman SM: Chemoprevention of Cancer, In Kufe DW, Pollock RE, Weichselbaum RR, et al (eds): Cancer Medicine. BC Becker Inc. Hamilton, London, Ontario, 2003, pp 413-422
59. Hong WK, Endicott J, Itri LM, et al: 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315:1501-1505, 1986
60. Lippman SM, Batsakis JG, Toth BB, et al: Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 328:15-20, 1993
61. Lotan R, Xu XC, Lippman SM, et al: Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 332:1405-1410, 1995
62. McGregor F, Muntoni A, Fleming J, et al: Molecular changes associated with oral dysplasia progression and acquisition of immortality: Potential for its reversal by 5-azacytidme. Cancer Res 62:4757-4766, 2002
63. Xu X-C, Zile MH, Lippman SM, et al: Anti-retinoic acid antibody binding to human premalignant oral lesions is lower than to normal tissue, is increased after 13-cis-retinoic acid treatment in vivo, and is related to retinoic acid receptor beta expression. Cancer Res 55:5507-5511, 1995
64. Youssef EM, Lotan D, Issa JP, et al: Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res 10:1733-1742, 2004
65. Song S, Xu XC: Effect of benzo[a]pyrene diol epoxide on expression of retinoic acid receptor-beta in immortalized esophageal epithelial cells and esophageal cancer cells. Biochem Biophys Res Commun 281:872-877, 2001
66. Li M, Song S, Lippman SM, et al: Induction of retinoic acid receptor-beta suppresses cyclo-oxygenase-2 expression in esophageal cancer cells. Oncogene 21:411-418, 2002
67. Lippman SM, Shin DM, Lee JJ, et al: p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res 55:16-19, 1995
68. Mao L, El-Naggar AK, Papadimitrakopoulou V, et al: Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 90:1545-1551, 1998
69. Lippman SM, Hong WK: Cancer prevention by delay. Clin Cancer Res 8:305-313, 2002
70. Izzo JG, Papadimitrakopoulou VA, Liu DD, et al: Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 95:198-205, 2003
71. Hong WK, Lippman SM, Itri LM, et al: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795-801, 1990
72. Benner SE, Pajak TF, Lippman SM, et al: Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: Long-term follow-up. J Natl Cancer Inst 86:140-141, 1994
73. Greenspan D, Jordan RC: The white lesion that kills-aneuploid dysplastic oral leukoplakia. N Engl J Med 350:1382-1384, 2004
74. Dannenberg AJ, Lippman SM, Mann JR, et al: Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention. J Clin Oncol 23:254-266, 2005
75. Moraitis D, Du B, De Lorenzo MS, et al: Levels of COX-2 are increased in the oral mucosa of smokers. Evidence for the role of EGFR and its ligands. Cancer Res: in press
76. Wiese FW, Thompson PA, Kadlubar FF: Carcinogen substrate specificity of human COX-1 and COX-2. Carcinogenesis 22:5-10, 2001
77. Nishimura M, Urade M, Hashitani S, et al: Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib. J Oral Pathol Med 33:614-621, 2004
78. Bosetti C, Talamini R, Franceschi S, et al: Aspirin use and cancers of the upper aerodigestive tract. Br J Cancer 88:672-674, 2003
79. Sudbø J, Søland TM, Ristimäki A, et al: COX-2 is selectively up-regulated in aneuploid oral leukoplakia: A rationale for targeted use of COX-2 inhibitors to prevent oral cancer Cancer Epidemiol Biomarkers Prev: in press
80. Steinbach G, Lynch PM, Phillips RK, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952, 2000
81. White WB, Faich G, Whelton A, et al: Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or dicofenac. Am J Cardiol 89:425-430, 2002
82. Grandis JR, Tweardy DJ: Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53:3579-3584, 1993
83. Shin DM, Ro JY, Hong WK, et al: Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54:3153-3159, 1994
84. Torrance CJ, Jackson PE, Montgomery E, et al: Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6:1024-1028, 2000
85. Chen Z, Zhang X, Li MF, et al: Simultaneously targeting EGFR tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res: in press
86. Zhang X, Chen Z, Choe MS, et al: Significant delay of tumor progression by ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with a cyclo-oxygenase-2 (COX-2) inhibitor, celecoxib, in a xenograft model for squamous cell carcinoma of the head and neck (SCCHN). Proc Am Assoc Cancer Res 45:726, 2004 (abstr 3136)
87. Mork J, Thoresen S, Faye-Lund H, et al: Head and neck cancer in Norway. A study of the quality of the Cancer Registry of Norway's data on head and neck cancer for the period 1953-1991. APMIS 103:375-382, 1995
88. Rudin CM, Cohen EE, Papadirnitrakopoulou VA, et al: An attenuated adenovirus, ONYX 015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 21:4546-4552, 2003
89. Clayman GL, el-Naggar AK, Lippman SM, et al: Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16:2221-2232, 1998
90. Sabichi AL, Subbarayan V, Llansa N, et al: Peroxisome proliferator-activated receptor-γ suppresses cyclooxygenase-2 expression in human prostate cells. Cancer Epidemiol Biomarkers Prev 13:1704-1709, 2004
91. Garnis C, Campbell J, Zhang L, et al: OCGR array: An oral cancer genomic regional array for comparative genomic hybridization analysis. Oral Oncol 40:511-519, 2004
92. Garnis C, Coe BP, Ishkanian A, et al: Novel regions of amplification on 8q distinct from the MYC locus and frequently altered in oral dysplasia and cancer. Genes Chromosomes Cancer 39:93-98, 2004